| Product Code: ETC9625540 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Taiwan Non-alcoholic Steatohepatitis Market Overview |
3.1 Taiwan Country Macro Economic Indicators |
3.2 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, 2021 & 2031F |
3.3 Taiwan Non-alcoholic Steatohepatitis Market - Industry Life Cycle |
3.4 Taiwan Non-alcoholic Steatohepatitis Market - Porter's Five Forces |
3.5 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Sales Channel, 2021 & 2031F |
3.7 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Disease Cause, 2021 & 2031F |
3.8 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Taiwan Non-alcoholic Steatohepatitis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of non-alcoholic steatohepatitis (NASH) in Taiwan due to changing lifestyles and rising obesity rates. |
4.2.2 Growing awareness about NASH among healthcare professionals and patients leading to early diagnosis and treatment. |
4.2.3 Favorable government initiatives and policies promoting awareness, screening, and treatment of NASH. |
4.3 Market Restraints |
4.3.1 Limited availability of approved treatment options for NASH in Taiwan. |
4.3.2 High cost associated with NASH diagnosis, treatment, and management. |
4.3.3 Lack of standardized guidelines for NASH diagnosis and treatment leading to variability in clinical practices. |
5 Taiwan Non-alcoholic Steatohepatitis Market Trends |
6 Taiwan Non-alcoholic Steatohepatitis Market, By Types |
6.1 Taiwan Non-alcoholic Steatohepatitis Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Vitamin E and Pioglitazone, 2021- 2031F |
6.1.4 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Ocaliva, 2021- 2031F |
6.1.5 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Elafibranor, 2021- 2031F |
6.1.6 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Selonsertib and Cenicriviroc, 2021- 2031F |
6.1.7 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Obeticholic Acid, 2021- 2031F |
6.1.8 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Taiwan Non-alcoholic Steatohepatitis Market, By Sales Channel |
6.2.1 Overview and Analysis |
6.2.2 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.2.3 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Online Providers, 2021- 2031F |
6.2.4 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.3 Taiwan Non-alcoholic Steatohepatitis Market, By Disease Cause |
6.3.1 Overview and Analysis |
6.3.2 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hypertension, 2021- 2031F |
6.3.3 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Heart Disease, 2021- 2031F |
6.3.4 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By High Blood Lipid, 2021- 2031F |
6.3.5 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Type 2 Diabetes, 2021- 2031F |
6.3.6 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Obesity, 2021- 2031F |
6.4 Taiwan Non-alcoholic Steatohepatitis Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 Taiwan Non-alcoholic Steatohepatitis Market Revenues & Volume, By Homecare settings, 2021- 2031F |
7 Taiwan Non-alcoholic Steatohepatitis Market Import-Export Trade Statistics |
7.1 Taiwan Non-alcoholic Steatohepatitis Market Export to Major Countries |
7.2 Taiwan Non-alcoholic Steatohepatitis Market Imports from Major Countries |
8 Taiwan Non-alcoholic Steatohepatitis Market Key Performance Indicators |
8.1 Number of NASH awareness campaigns conducted in Taiwan. |
8.2 Percentage of healthcare professionals trained in NASH diagnosis and management. |
8.3 Average time taken for NASH diagnosis from initial symptoms presentation. |
8.4 Patient adherence rates to NASH treatment protocols. |
8.5 Number of clinical trials for NASH treatment being conducted in Taiwan. |
9 Taiwan Non-alcoholic Steatohepatitis Market - Opportunity Assessment |
9.1 Taiwan Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Taiwan Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Sales Channel, 2021 & 2031F |
9.3 Taiwan Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Disease Cause, 2021 & 2031F |
9.4 Taiwan Non-alcoholic Steatohepatitis Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Taiwan Non-alcoholic Steatohepatitis Market - Competitive Landscape |
10.1 Taiwan Non-alcoholic Steatohepatitis Market Revenue Share, By Companies, 2024 |
10.2 Taiwan Non-alcoholic Steatohepatitis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here